Pfizer (PFE) News Today

Pfizer Inc. (PFE) stock is trading higher today, driven by a series of positive clinical updates and bullish investor signals, although some longer-term headwinds remain.

• Positive Sentiment: Pfizer advanced HYMPAVZI after promising hemophilia trial results, highlighting the strength of its gene therapy pipeline. Pfizer Advances HYMPAVZI After Successful Hemophilia Trial Results
• Positive Sentiment: Unusual volume in Pfizer put options signals investors are positioning for upside, reflecting a bullish outlook. Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook
• Positive Sentiment: Options activity shows spikes in call premiums, indicating traders expect higher share prices. Pfizer: Options Activity Speaks Bullish
• Positive Sentiment: Technical momentum confirmed as PFE has traded above its 50-day moving average for over a month. Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
• Positive Sentiment: Elranatamab study in multiple myeloma shows encouraging early data, underscoring potential for a major oncology franchise. Pfizer’s Promising Study on Elranatamab for Multiple Myeloma
• Positive Sentiment: ABRYSVO RSV vaccine and Phase 3 maternal RSV study report positive effectiveness, boosting Pfizer’s vaccine pipeline prospects. Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for RSV Prevention
• Positive Sentiment: ARV-471 breast cancer trial posts strong Phase 3 results, pointing to a new growth driver in oncology. Pfizer’s ARV-471: A Promising New Hope for Advanced Breast Cancer
• Neutral Sentiment: Reports suggest ex-Florida AG Pam Bondi’s DOJ policy changes may have indirectly benefited Pfizer, though material impact is unclear. Bondi made changes to DOJ policy. Her former client Pfizer might have benefited
• Neutral Sentiment: A commentary questions whether Pfizer’s attractive dividend yield masks slower growth and fading COVID franchise tailwinds. Is Pfizer Stock a Yield Trap?
• Negative Sentiment: FDA will recommend COVID-19 vaccines only for seniors and high-risk groups, limiting the addressable market for Pfizer’s COVID portfolio. Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)